| David S Cornelder, DO | |
|
1801 Hickman Rd, Des Moines, IA 50314-1505 | |
| (515) 282-2200 | |
| (515) 282-2332 |
| Full Name | David S Cornelder |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 1801 Hickman Rd, Des Moines, Iowa |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174759740 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 4119 (Iowa) | Primary |
| Entity Name | Broadlawns Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467447508 PECOS PAC ID: 3678466166 Enrollment ID: O20040206000913 |
News Archive
The use of antimicrobial impregnated scrubs combined with good hand hygiene is effective in reducing the burden of Methicillin-Resistant Staphylococcus Aureus (MRSA) on healthcare workers' apparel and may potentially play a role in decreasing the risk of MRSA transmission to patients, according to a new study from Virginia Commonwealth University researchers.
A new study published in the November 19, 2019 issue of JAMA shows that a newly developed small molecule drug called ubrogepant may successfully fight migraine at doses of 25 and 50 mg, with pain relief at 2 hours with both doses, while the most troublesome symptom of migraine was held off at 2 hours post-dose with the 50 mg dose. This may help millions of migraine patients to achieve pain relief and function better.
QRxPharma Limited announced today the United States Food and Drug Administration has issued a Complete Response Letter regarding the Moxduo New Drug Application for the treatment of moderate to severe acute pain.
A new approach to better select breast cancer patients in need of urgent surgery or chemotherapy during the COVID-19 pandemic has been developed by researchers at The Royal Marsden and the Breast Cancer Now Research Centre at The Institute of Cancer Research, London, in collaboration with colleagues in the UK, Germany and US.
› Verified 1 days ago
| Entity Name | Mahaska County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639159304 PECOS PAC ID: 2769388677 Enrollment ID: O20041202000965 |
News Archive
The use of antimicrobial impregnated scrubs combined with good hand hygiene is effective in reducing the burden of Methicillin-Resistant Staphylococcus Aureus (MRSA) on healthcare workers' apparel and may potentially play a role in decreasing the risk of MRSA transmission to patients, according to a new study from Virginia Commonwealth University researchers.
A new study published in the November 19, 2019 issue of JAMA shows that a newly developed small molecule drug called ubrogepant may successfully fight migraine at doses of 25 and 50 mg, with pain relief at 2 hours with both doses, while the most troublesome symptom of migraine was held off at 2 hours post-dose with the 50 mg dose. This may help millions of migraine patients to achieve pain relief and function better.
QRxPharma Limited announced today the United States Food and Drug Administration has issued a Complete Response Letter regarding the Moxduo New Drug Application for the treatment of moderate to severe acute pain.
A new approach to better select breast cancer patients in need of urgent surgery or chemotherapy during the COVID-19 pandemic has been developed by researchers at The Royal Marsden and the Breast Cancer Now Research Centre at The Institute of Cancer Research, London, in collaboration with colleagues in the UK, Germany and US.
› Verified 1 days ago
| Entity Name | Mahaska County Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1356320659 PECOS PAC ID: 2769388677 Enrollment ID: O20061104000235 |
News Archive
The use of antimicrobial impregnated scrubs combined with good hand hygiene is effective in reducing the burden of Methicillin-Resistant Staphylococcus Aureus (MRSA) on healthcare workers' apparel and may potentially play a role in decreasing the risk of MRSA transmission to patients, according to a new study from Virginia Commonwealth University researchers.
A new study published in the November 19, 2019 issue of JAMA shows that a newly developed small molecule drug called ubrogepant may successfully fight migraine at doses of 25 and 50 mg, with pain relief at 2 hours with both doses, while the most troublesome symptom of migraine was held off at 2 hours post-dose with the 50 mg dose. This may help millions of migraine patients to achieve pain relief and function better.
QRxPharma Limited announced today the United States Food and Drug Administration has issued a Complete Response Letter regarding the Moxduo New Drug Application for the treatment of moderate to severe acute pain.
A new approach to better select breast cancer patients in need of urgent surgery or chemotherapy during the COVID-19 pandemic has been developed by researchers at The Royal Marsden and the Breast Cancer Now Research Centre at The Institute of Cancer Research, London, in collaboration with colleagues in the UK, Germany and US.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David S Cornelder, DO 1801 Hickman Rd, Des Moines, IA 50314-1505 Ph: (515) 282-2200 | David S Cornelder, DO 1801 Hickman Rd, Des Moines, IA 50314-1505 Ph: (515) 282-2200 |
News Archive
The use of antimicrobial impregnated scrubs combined with good hand hygiene is effective in reducing the burden of Methicillin-Resistant Staphylococcus Aureus (MRSA) on healthcare workers' apparel and may potentially play a role in decreasing the risk of MRSA transmission to patients, according to a new study from Virginia Commonwealth University researchers.
A new study published in the November 19, 2019 issue of JAMA shows that a newly developed small molecule drug called ubrogepant may successfully fight migraine at doses of 25 and 50 mg, with pain relief at 2 hours with both doses, while the most troublesome symptom of migraine was held off at 2 hours post-dose with the 50 mg dose. This may help millions of migraine patients to achieve pain relief and function better.
QRxPharma Limited announced today the United States Food and Drug Administration has issued a Complete Response Letter regarding the Moxduo New Drug Application for the treatment of moderate to severe acute pain.
A new approach to better select breast cancer patients in need of urgent surgery or chemotherapy during the COVID-19 pandemic has been developed by researchers at The Royal Marsden and the Breast Cancer Now Research Centre at The Institute of Cancer Research, London, in collaboration with colleagues in the UK, Germany and US.
› Verified 1 days ago
Neetha Molakala, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 University Ave, Suite 120, Des Moines, IA 50314 Phone: 515-248-1500 Fax: 515-248-1510 | |
Matthew Helmick Williams, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1801 Hickman Rd, Des Moines, IA 50314 Phone: 515-282-5640 Fax: 515-282-2332 | |
Todd Eberle, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1111 6th Ave, Des Moines, IA 50314 Phone: 515-643-8678 Fax: 515-643-5802 | |
Evan Douglas Peterson, PA-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6520 Se 14th St, Des Moines, IA 50320 Phone: 515-953-1500 Fax: 515-953-2136 | |
April Winters, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2353 Se 14th St, Des Moines, IA 50320 Phone: 515-248-1400 Fax: 515-248-1414 | |
Kelli A Roenfanz, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 840 East University Avenue, Des Moines, IA 50316 Phone: 515-265-4211 Fax: 515-309-5993 | |
Dr. Sarah Sweeney Gude, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3509 E 29th St, Des Moines, IA 50317 Phone: 515-248-1600 Fax: 515-248-1610 |